---
title: "Dual immune checkpoint inhibition for melanoma brain metastases: safety and efficacy meta-analysis"
id: "pubmed-42934318"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42934318"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42934318/"
doi: "10.1007/s10143-026-04538-w"
published_at: "2026-10-27T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Dual immune checkpoint inhibition for melanoma brain metastases: safety and efficacy meta-analysis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42934318
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42934318/)
- **DOI:** [10.1007/s10143-026-04538-w](https://doi.org/10.1007%2Fs10143-026-04538-w)
- **Published At:** 2026-10-27T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The authors performed a PRISMA-based systematic review and meta-analysis of prospective and retrospective studies assessing **dual immune checkpoint inhibition** in adults with cutaneous or mucosal **melanoma brain metastases**. - Literature searches covered PubMed, Scopus, and Embase through November 5, 2025; random-effects models were used to pool outcomes. - Twenty-four studies including 3,518 patients were included; pooled intracranial progression-free survival (iPFS) was reported at multiple timepoints. - Pooled iPFS: 51.9% at 6 months, 44.1% at 12 months, 40.5% at 2 years, and 38.8% at 3 years. - Pooled intracranial objective response rate (iORR) across dual-ICI recipients was 42.5%; iORR rose to 48% when dual ICI was given as first-line therapy. - Outcomes differed by symptom status: asymptomatic patients had better survival than symptomatic patients (3-year OS 52.3% vs 31.5%). - Elevated lactate dehydrogenase (LDH) correlated with worse survival in pooled analyses; BRAF mutation status was not significantly associated with outcomes. - Safety signals: 78% experienced all-grade treatment-related adverse events, 48.2% had grade ≥3 events, and 65.5% had all-grade immune-related adverse events. - Comparative analyses versus ICI monotherapy favored dual ICI for overall survival at 6 months, 12 months, and 2 years; no significant 3-year OS difference was observed. - Across studies reporting toxicity for both dual and mono ICI, dual therapy was consistently associated with higher rates of treatment-related and immune-related toxicities, consistent with known **nivolumab plus ipilimumab** profiles. - The authors noted heterogeneity across included studies and limited long-term data contributing to uncertainty about a sustained 3-year survival advantage; symptomatic disease remains an unmet need requiring balanced consideration of toxicity.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42934318/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42934318%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42934318/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42934318/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42934318/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42934318/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42934318/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42934318/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42934318%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42934318%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42934318/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42934318/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42934318/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42934318/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42934318/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42934318/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42934318/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42934318/#conflict-of-interest) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42934318/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42934318/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42934318/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42934318/#substances) Title & authors Abstract Conflict of interest statement References Publication types MeSH terms Substances Review Neurosurg Rev Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neurosurg+Rev%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Neurosurg+Rev%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934318/) . 2026 Oct 27;49(1):624. doi: 10.1007/s10143-026-04538-w. # Safety and efficacy of dual immune checkpoint inhibition for melanoma brain metastases and its comparison to ICI monotherapy: A systematic review and meta-analysis [Alireza Shariati](https://pubmed.ncbi.nlm.nih.gov/?term=Shariati+A&cauthor_id=42934318)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#full-view-affiliation-1 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. shariati.alireza20@gmail.com."), [Ehsan Mehrtabar](https://pubmed.ncbi.nlm.nih.gov/?term=Mehrtabar+E&cauthor_id=42934318)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#full-view-affiliation-2 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran."), [Taher Fanihagh](https://pubmed.ncbi.nlm.nih.gov/?term=Fanihagh+T&cauthor_id=42934318)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#full-view-affiliation-2 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran."), [Reza Moghaddam](https://pubmed.ncbi.nlm.nih.gov/?term=Moghaddam+R&cauthor_id=42934318)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#full-view-affiliation-2 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran."), [Pouria Delbari](https://pubmed.ncbi.nlm.nih.gov/?term=Delbari+P&cauthor_id=42934318)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#full-view-affiliation-2 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran."), [Saba Mehrtabar](https://pubmed.ncbi.nlm.nih.gov/?term=Mehrtabar+S&cauthor_id=42934318)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#full-view-affiliation-3 "Department of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran."), [Reza Ghalehtaki](https://pubmed.ncbi.nlm.nih.gov/?term=Ghalehtaki+R&cauthor_id=42934318)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#full-view-affiliation-2 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#full-view-affiliation-4 "Department of Radiation Oncology, Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.") Affiliations Expand ### Affiliations * 1 School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. shariati.alireza20@gmail.com. * 2 School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. * 3 Department of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran. * 4 Department of Radiation Oncology, Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. * PMID: **42934318** * DOI: [ 10.1007/s10143-026-04538-w ](https://doi.org/10.1007/s10143-026-04538-w) Item in Clipboard Review # Safety and efficacy of dual immune checkpoint inhibition for melanoma brain metastases and its comparison to ICI monotherapy: A systematic review and meta-analysis Alireza Shariati et al. Neurosurg Rev. 2026. Show details Display options Display options Format Abstract PubMed PMID Neurosurg Rev Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neurosurg+Rev%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Neurosurg+Rev%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934318/) . 2026 Oct 27;49(1):624. doi: 10.1007/s10143-026-04538-w. ### Authors [Alireza Shariati](https://pubmed.ncbi.nlm.nih.gov/?term=Shariati+A&cauthor_id=42934318)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#short-view-affiliation-1 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. shariati.alireza20@gmail.com."), [Ehsan Mehrtabar](https://pubmed.ncbi.nlm.nih.gov/?term=Mehrtabar+E&cauthor_id=42934318)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#short-view-affiliation-2 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran."), [Taher Fanihagh](https://pubmed.ncbi.nlm.nih.gov/?term=Fanihagh+T&cauthor_id=42934318)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#short-view-affiliation-2 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran."), [Reza Moghaddam](https://pubmed.ncbi.nlm.nih.gov/?term=Moghaddam+R&cauthor_id=42934318)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#short-view-affiliation-2 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran."), [Pouria Delbari](https://pubmed.ncbi.nlm.nih.gov/?term=Delbari+P&cauthor_id=42934318)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#short-view-affiliation-2 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran."), [Saba Mehrtabar](https://pubmed.ncbi.nlm.nih.gov/?term=Mehrtabar+S&cauthor_id=42934318)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#short-view-affiliation-3 "Department of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran."), [Reza Ghalehtaki](https://pubmed.ncbi.nlm.nih.gov/?term=Ghalehtaki+R&cauthor_id=42934318)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#short-view-affiliation-2 "School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42934318/#short-view-affiliation-4 "Department of Radiation Oncology, Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.") ### Affiliations * 1 School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. shariati.alireza20@gmail.com. * 2 School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. * 3 Department of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran. * 4 Department of Radiation Oncology, Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. * PMID: **42934318** * DOI: [ 10.1007/s10143-026-04538-w ](https://doi.org/10.1007/s10143-026-04538-w) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Melanoma brain metastases remain a major cause of morbidity and death despite advances in systemic therapy. Dual immune checkpoint inhibition has shown promising intracranial activity, but the overall evidence is heterogeneous and its benefit relative to monotherapy remains clinically important to define. We performed a PRISMA-based systematic review and meta-analysis of prospective and retrospective studies evaluating dual immune checkpoint inhibition in adults with cutaneous or mucosal melanoma brain metastases. PubMed, Scopus, and Embase were searched from inception to November 5, 2025. Random-effects models were used to pool intracranial progression-free survival, overall survival, intracranial response outcomes, and adverse events. Comparative analyses versus monotherapy were performed when data were available. Twenty-four studies involving 3518 patients were included. In the overall dual ICI cohort, pooled intracranial progression-free survival was 51.9% at 6 months, 44.1% at 12 months, 40.5% at 2 years, and 38.8% at 3 years. Pooled intracranial objective response rate was 42.5%, increasing to 48% in first-line dual ICI recipients. Outcomes were more favorable in asymptomatic patients than in symptomatic patients, with pooled overall survival at 3 years of 52.3% versus 31.5%. Comparative analyses favored dual ICI over monotherapy for overall survival at 6 months, 12 months, and 2 years, while no significant difference was seen at 3 years. Elevated LDH was associated with worse survival, whereas BRAF mutation was not significantly associated with outcome. All-grade treatment-related adverse events occurred in 78% of patients, grade 3 or higher events in 48.2%, and all-grade immune-related adverse events in 65.5%. Across studies reporting adverse events for patients receiving dual and mono ICI, dual ICI therapy was consistently associated with higher rates of treatment-related and immune-related toxicities, which is consistent with the established safety profile of nivolumab plus ipilimumab and highlights the need for close monitoring, and early management of immune-related complications. Dual immune checkpoint inhibition provides meaningful and durable intracranial benefit in melanoma brain metastases, particularly in asymptomatic patients and when used early. Comparative analyses favored dual ICI over monotherapy at 6 months, 12 months, and 2 years. However, the 3-year survival advantage remains uncertain because of limited data and substantial heterogeneity. Symptomatic disease remains a major unmet need, and the potential survival benefit must be balanced against substantial toxicity. © 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declarations. Ethics approval and consent to participate: Not applicable. Competing interests: The authors declare no competing interests. Clinical trial number: Not applicable ## References 1. 1. Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN et al (2016) Challenges in the delivery of therapies to melanoma brain metastases. Curr Pharmacol Rep 2(6):309–325. - [DOI](https://doi.org/10.1007/s40495-016-0072-z) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/28546917/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/5440090/) 2. 1. Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S (2015) Evolving treatment options for melanoma brain metastases. Lancet Oncol 16(13):e486–e497. - [DOI](https://doi.org/10.1016/s1470-2045\(15\)00141-2) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/26433822/) 3. 1. Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D et al (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40(5):492–516. - [DOI](https://doi.org/10.1200/jco.21.02314) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/34932393/) 4. 1. Chaung KV, Sloan AE, Choi S (2021) Limited brain metastases: a narrative review. Ann Palliat Med 10(5):6016–6027. - [DOI](https://doi.org/10.21037/apm-21-363) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/33977758/) 5. 1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. - [DOI](https://doi.org/10.1056/nejmoa1003466) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/20525992/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/3549297/) Show all 43 references ## Publication types * Systematic Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Systematic+Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Systematic+Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934318/) * Meta-Analysis Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Meta-Analysis%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Meta-Analysis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934318/) * Comparative Study Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Comparative+Study%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Comparative+Study) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934318/) * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934318/) ## MeSH terms * Brain Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Brain+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Brain+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934318/) * Brain Neoplasms* / secondary Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Brain+Neoplasms%2Fsecondary%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Brain+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934318/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934318/) * Immune Checkpoint Inhibitors* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immune+Checkpoint+Inhibitors%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Immune+Checkpoint+Inhibitors) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934318/) * Melanoma* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Melanoma%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Melanoma)
## Related Clinical Research

- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [VE800 Plus Nivolumab Phase 1 (CONSORTiUM-IO) in Select Refractory or Metastatic Cancers](https://medichelpline.com/clinical-feed/medrxiv-13-consortium-io-a-phase-1-study-evaluating-ve800-plus-nivolumab-in-treatment-of.md)
- [Ipilimumab plus Nivolumab Yields 50% Observed ORR in Small WD‑NET Phase II Cohort](https://medichelpline.com/clinical-feed/frontiers-in-immunology-4-dual-immune-checkpoint-blockade-in-advanced-well-differentiated-neuroendocrine.md)
- [Amsokigene autoleucel TIL Therapy Shows Promise in ICI-Resistant Advanced Melanoma Trials](https://medichelpline.com/clinical-feed/nature-1-regulatable-membrane-bound-il-15-engineered-til-cell-therapy-for-immune.md)
- [Relatlimab plus nivolumab 5-year outcomes in advanced melanoma: RELATIVITY-047 survival and biomar](https://medichelpline.com/clinical-feed/nature-0-relatlimab-plus-nivolumab-versus-nivolumab-for-advanced-melanoma-5-year.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.